Newsroom

Sorted by: Latest
-

Riassunto: Crown Bioscience aderisce alla NAM Developer Coalition del C-Path per promuovere modelli rilevanti per gli umani nello sviluppo di farmaci

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, un'organizzazione di ricerca a contratto (CRO) specializzata nella scoperta e nello sviluppo di farmaci oncologici, oggi ha annunciato l'adesione alla New Approach Methodologies Developer Coalition (NAMs-DC) del Critical Path Institute (C-Path), un'iniziativa collaborativa dedicata alla promozione della convalida, della qualifica e dell'adozione normativa di metodi di ricerca innovativa rilevanti per gli umani. Crown Bioscience entra a far parte di...
-

Samenvatting: Crown Bioscience sluit zich aan bij de NAMs Developer Coalition van C-Path om mensrelevante modellen in de geneesmiddelenontwikkeling te bevorderen

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, een wereldwijd opererende contractonderzoeksorganisatie (CRO) die gespecialiseerd is in het ontdekken en ontwikkelen van oncologische geneesmiddelen, heeft vandaag bekendgemaakt dat het zich heeft aangesloten bij de New Approach Methodologies Developer Coalition (NAMs-DC) (Coalitie van ontwikkelaars van nieuwe aanpakmethoden) van het Critical Path Institute (C-Path). Dit samenwerkingsinitiatief heeft als doel de validatie, kwalificatie en wettelijke...
-

Resumen: Crown Bioscience se incorpora a la Coalición de Desarrolladores de NAM de C-Path con el objetivo de impulsar modelos relevantes para el ser humano en el desarrollo de fármacos

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, una organización de investigación por contrato (CRO) global especializada en el descubrimiento y el desarrollo de fármacos, anunció hoy su incorporación a la Coalición de Desarrolladores de Metodologías de Nuevo Enfoque de Critical Path Institute (C-Path), una iniciativa de colaboración que se dedica a impulsar la validación, la cualificación y la adopción regulatoria de innovadores métodos de investigación relevantes para el ser humano. Crown Biosc...
-

Crown Bioscience tritt der NAMs-Entwicklerkoalition von C-Path bei, um die Entwicklung von für Menschen relevante Modelle in der Arzneimittelentwicklung voranzutreiben

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience ist ein weltweit tätiges Auftragsforschungsinstitut (Contract Research Organisation -CRO), das sich auf die Erforschung und Entwicklung von Krebsmedikamenten spezialisiert hat. Es gab heute bekannt, dass es der „New Approach Methodologies Developer Coalition“ (NAMs-DC) des Critical Path Institute (C-Path) beigetreten ist, einer Kooperationsinitiative, die sich der Förderung der Validierung, Qualifizierung und behördlichen Anerkennung innovativer, für...
-

From Computation to Coating: Argonne Accelerates Search for Solid-state Battery Materials

LEMONT, Ill.--(BUSINESS WIRE)--Researchers offer a more predictive alternative to trial and error for evaluating materials at some of a battery’s most vulnerable interfaces....
-

Independent Bank Corp. Reports Second Quarter Net Income of $81.8 Million

ROCKLAND, Mass.--(BUSINESS WIRE)--Independent Bank Corp. (Nasdaq Global Select Market: INDB), parent of Rockland Trust Company, today announced 2026 second quarter net income of $81.8 million, or $1.70 per diluted share, as compared to 2026 first quarter net income of $79.9 million, or $1.63 per diluted share. Excluding merger-related costs associated with the Company’s third quarter 2025 acquisition of Enterprise Bancorp, Inc. (“Enterprise”) and its subsidiary, Enterprise Bank, and their relat...
-

ArcBest Simplifies Brand Structure and Streamlines Operations to Drive Long-Term Growth and Efficiency

FORT SMITH, Ark.--(BUSINESS WIRE)--ArcBest announces simplified brand structure: MoLo Solutions, Panther Premium Logistics and ArcBest Technologies will become ArcBest effective Aug. 1....
-

Alcoa Corporation Reports Second Quarter 2026 Results

PITTSBURGH--(BUSINESS WIRE)--Alcoa Corporation (NYSE: AA; ASX: AAI) (Alcoa or the Company) today reported results for the second quarter 2026 that included record quarterly revenue, strong operational performance, and progress on multiple smelter capacity restarts, in addition to the announced acquisition of South32 Limited’s (South32) interests in its bauxite, alumina, and aluminum assets. Financial Results and Highlights M, except per share amounts 2Q26   1Q26   2Q25   Revenue $ 3,966   $ 3,1...
-

John B. Sanfilippo & Son, Inc. Announces CEO Transition and Leadership Changes

ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) today announced a CEO and leadership succession plan designed to ensure a seamless leadership transition and the continued execution of its strategic plan. Jeffrey T. Sanfilippo, Chairman of the Board of Directors and Chief Executive Officer, will transition to the role of Executive Chairman, effective October 1, 2026. In this capacity, Mr. Sanfilippo will continue to lead the Board of Directors and work closely wit...
-

Steel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance Failures

NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), a significant, long-standing shareholder of InMode Ltd. (“InMode” or the “Company”) (Nasdaq: INMD), today issued a letter to the Board of Directors (the “Board”) of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 2069206 Israel Attention: The Board of Directors Dear Members of the Board of Directors:...